Heme oxygenase-1-transduced bone marrow mesenchymal stem cells in reducing acute rejection and improving small bowel transplantation outcomes in rats by Yang Yang et al.
RESEARCH Open Access
Heme oxygenase-1-transduced bone
marrow mesenchymal stem cells in
reducing acute rejection and improving
small bowel transplantation outcomes in
rats
Yang Yang1, Hong Li Song1,2*, Wen Zhang1, Ben Juan Wu1, Nan Nan Fu1, Chong Dong1 and Zhong Yang Shen1*
Abstract
Background: We determined whether bone marrow mesenchymal stem cells (BMMSCs) transduced with heme
oxygenase-1 (HO-1), a cytoprotective and immune-protective factor, could improve outcomes for small bowel
transplantation (SBTx) in rats.
Methods: We performed heterotopic SBTx from Brown Norway rats to Lewis rats, before infusing Ad/HO-1-transduced
BMMSCs (Ad/HO-1/BMMSCs) through the superficial dorsal veins of the penis. Respective infusions with Ad/BMMSCs,
BMMSCs, and normal saline served as controls. The animals were sacrificed after 1, 5, 7, or 10 days. At each time point,
we measured small bowel histology and apoptosis, HO-1 protein and mRNA expression, natural killer (NK) cell activity,
cytokine concentrations in serum and intestinal graft, and levels of regulatory T (Treg) cells.
Results: The saline-treated control group showed aggravated acute cellular rejection over time, with mucosal destruction,
increased apoptosis, NK cell activation, and upregulation of proinflammatory and immune-related mediators. Both the
Ad/BMMSC-treated group and the BMMSC-treated group exhibited attenuated acute cellular rejection at an early
stage, but the effects receded 7 days after transplantation. Strikingly, the Ad/HO-1/BMMSC-treated group demonstrated
significantly attenuated acute cellular rejection, reduced apoptosis and NK cell activity, and suppressed concentrations
of inflammation and immune-related cytokines, and upregulated expression of anti-inflammatory cytokine mediators
and increased Treg cell levels.
Conclusion: Our data suggest that Ad/HO-1-transduced BMMSCs have a reinforced effect on reducing acute rejection
and protecting the outcome of SBTx in rats.
Keywords: Acute cellular rejection, Bone marrow mesenchymal stem cells, Heme oxygenase-1, Small bowel
transplantation
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Background
Nowadays, small bowel transplantation (SBTx) is the
sole therapeutic option for patients with irreversible
intestinal failure. However, due to the difficulties associ-
ated with the allogeneic immune response, long-term
curative effects of SBTx are not comparable with other
organ transplantations. Although graft rejection rates for
isolated intestinal transplants have decreased from 80%
to 30–40% at experienced transplant centers, rejection
remains the leading cause of graft failure or loss, and sub-
sequently the main obstacle for further development of
SBTx [1–3]. Moreover, administration of immunosuppres-
sive agents to control rejection often causes unfavorable
side effects [4].
Mesenchymal stem cells (MSCs) are multipotent non-
hematopoietic progenitor cells of stromal origin that can
be isolated from the bone marrow or other tissues (e.g.,
cord blood or adipose tissue) [5] and differentiate into
mesoderm-originated cells (osteoblasts, chondrocytes,
adipocytes, cardiocytes, etc.), ectoderm-originated cells
(nerve cells), and endoderm-originated cells (hepatic
oval cells) [6–10]. MSCs have the ability of homing to
target tissue. Many studies referring to MSC tracing
have demonstrated that intravenously engrafted MSCs
are mostly intercepted by microvessels of the lung, heart,
liver, kidney, etc., as well as homing to inflammatory and
injured areas [11–14]. Importantly, MSCs have been
shown to have regenerative, anti-inflammatory, and
immunomodulatory capabilities [15–17]. Many experi-
ments and early clinical trials have indicated that MSCs
can block the rejection or even induce immune toler-
ance following transplantation [18, 19]. However, the
therapeutic effects of MSCs in transplantation are largely
restricted by the limited survival rate in vivo [20].
Reports state that there is an obvious reduction in MSCs
4 days after engraftment, and the survival rate for more
than 1 week is less than 1% because of ischemia, anoxia,
and the inflammation response [21–25]. Outcomes have
the potential to be improved if MSCs are accompanied
with specific genetically engineered vectors designed to
improve the MSC survival rate.
Heme oxygenase (HO) is the rate-limiting enzyme in
the degradation of heme to biliverdin, and subsequently to
bilirubin [26]. HO-1, an inducible isoform of HO, is a
potent cytoprotective enzyme shown to exhibit anti-
inflammatory properties, anti-ischemia–reperfusion injur-
ies, and anti-apoptotic properties [27–29]. In addition,
HO-1 has been described as an immunosuppressive
molecule and proven to exhibit immunosuppressive
effects in adult rat and human MSCs [30, 31]. Importantly,
HO-1 represents an endogenous defensive system in
organ transplantation and prolonged graft survival [29]. In
rodent models, studies have implicated that enhanced
HO-1 expression attenuates transplant rejection [32].
Therefore, in this study, we transduced bone marrow
MSCs (BMMSCs) with an adenoviral vector carrying the
heme oxygenase gene (Ad/HO-1) and infused them into
rats after SBTx in order to investigate whether HO-1 gene
infection improves the MSC survival rate in vivo and
whether Ad/HO-1-transduced MSCs (Ad/HO-1/MSCs)




Inbred male Brown Norway (BN) rats (RT-1n) and male
Lewis rats (RT-1l) were purchased from Vital River
Company (Beijing, China). Adult BN rats (180–200 g)
and Lewis rats (200–220 g) were used as donors and re-
cipients, respectively. Immature Lewis rats (80–100 g)
(n = 25) were used as a source of BMMSCs. A total of
120 donors (BN rats) and 120 recipients (Lewis rats)
were used for SBTx. Of these, 20 recipients (five each in
the four groups) were used for survival rate analysis after
SBTx. The other 100 recipients were used for sample
collection following SBTx (naïve, n = 5; 1 day, n = 5;
5 days, n = 5; 7 days, n = 5; 10 days, n = 5 in each of
the four groups). All animals were treated humanely
and housed individually in standard animal facilities,
and maintained on a 12:12-h light/dark cycle in a
temperature-controlled room (25 °C). Animals were
monitored regularly and fed adaptively for at least
3 days before surgery. Rat chow and tap water were
provided ad libitum until animals were fasted 24 h
prior to surgery. This experiment was carried out
under strict accordance with the Guide for the Care
and Use of Laboratory Animals published by the
National Institutes of Health (NIH Publication 86–23,
revised 1985), and all protocols were approved by the
Animal Care and Research Committee of Tianjin First
Central Hospital, Tianjin, China (Permit Number:
E20140525-001A). All surgeries and sacrifices were
performed under chloral hydrate anesthesia. Every
effort was made to minimize animal suffering.
Preparation and identification of Ad/HO-1/BMMSCs
BMMSC isolation, culture, and characterization tech-
niques were as described previously by our group [33].
Briefly, BMMSCs were isolated from the femur and tibia
of male Lewis rats (80–100 g) and cultured in a cell cul-
ture incubator. The culture medium was changed and the
cells were consistently passaged when 80% confluence
was achieved. Following the third passage, BMMSCs were
collected for infusion or transduced with adenovirus.
Transduction was performed when the third-passage
BMMSCs reached 70–80% confluence. Briefly, culture
media were renewed and Ad/HO-1 (Jikai, Shanghai,
China) was added at a multiplicity of infection (MOI) of
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10. The media containing Ad/HO-1 was replaced after
6–8 h of culture. Ad/HO-1/BMMSCs were trypsinized,
washed, centrifuged, and resuspended at 1 × 107 cells/ml
in Dulbecco’s Modified Eagle’s medium (DMEM) for infu-
sion after 48–72 h of culture. Molecular biological features
of Ad/HO-1/BMMSCs were assessed by osteogenic differ-
entiation and adipogenic differentiation abilities in vitro,
as well as phenotype identification by flow cytometry
(FACSCalibur; BD, Alaska, MN, USA), and stained with
antibodies against CD29, CD34, CD45, CD90, RT1A, and
RT1B (Biolegend, San Diego, CA, USA).
Detection of HO-1 expression in Ad/HO-1/BMMSCs
Immunocytochemical staining and western blot analysis
were performed to determine whether the HO-1 gene
could be overexpressed successfully in BMMSCs trans-
duced with Ad/HO-1. Briefly, for immunohistochemical
staining, Ad/HO-1/BMMSCs were stained with a mouse
anti-rat HO-1 antibody (Abcam, USA) and TRITC-
conjugated goat anti-mouse IgG antibody. The cell
nuclei were stained with 4,6′-diamidino-2-phenylindole
dihydrochloride (DAPI). For western blot analysis, total
protein was released from cells for gel electrophoresis,
and then the separated proteins were transblotted from
gel to membrane and incubated with polyclonal rabbit
anti-rat HO-1 antibody (Stressgen Biotechnologies,
Victoria, BC, Canada) and goat anti-rabbit IgG second
antibody, respectively. Reactive protein was exposed
under the ECL chemiluminescence system.
Surgical procedures and experimental protocol
Both the donor and recipient rats were randomly
assigned to an experimental group and three control
groups. Heterotopic SBTx was performed allogeneically
from BN (RT1n) rats to Lewis (RT1l) rats as described in
our previous study [34]. For the Ad/HO-1/BMMSC
treatment group, recipient rats were treated with 1 × 107
Ad/HO-1/BMMSCs through the superficial dorsal veins
of the penis immediately after surgery. Control rats were
treated with 1 × 107 Ad/BMMSCs or 1 × 107 BMMSCs.
Isopycnic saline infusions served as the allogeneic con-
trol (Allo). The animals were monitored after surgery
three times per day at least and the weight loss was
recorded. The animals were euthanized via an intraperi-
toneal injection containing excessive chloral hydrate due
to pain and suffering experienced from surgical compli-
cations and acute rejection. A total of five animals per
group were sacrificed 1, 5, 7, and 10 days after SBTx
under chloral hydrate anesthesia.
Survival rate of the recipients
We observed the survival rate and quality of life in five
recipient rats per group. The survival rates of the recipi-
ents were compared between groups by Kaplan–Meier
analysis, and a log-rank test was used to identify any sig-
nificant differences between the groups. Differences were
considered statistically significant when P ≤ 0.05. Data
are presented as the mean ± standard deviation (SD).
Clinical manifestation and weight loss of the recipients
The recipients were observed carefully following surgery
and graded based on their clinical manifestations, including
grooming, mental state, activity, and response to stimula-
tion (0 was scored for normality, 1, 2, and 3 were scored
for mild, moderate, and severe change, respectively). Body
weight changes were precisely recorded at each time point.
Western blot analysis of intestine HO-1
Total cell proteins from intestinal grafts were released
using Complete Lysis M reagent (Roche, Germany) ac-
cording to the manufacturer’s instructions. Then, 50 μg
protein samples were boiled for 5 min in loading buffer
containing 4% sodium dodecyl sulfate (SDS), 20%
glycerol, and bromophenol blue. Proteins were sepa-
rated by 10% and 8% sodium dodecyl sulfate-
polyacryl-amide gel electrophoresis (SDS-PAGE) and
transblotted onto a polyvinylidene fluoride membrane
(Roche, Germany). Nonspecific reactivity was blocked
using 5% nonfat dry milk in TBST (10 mmol/L Tris–
HCl (pH 7.5), 150 mmol/L NaCl, 0.05% Tween-20) for
1 h at room temperature. The membrane was then in-
cubated with polyclonal rabbit anti-rat HO-1 antibody
(Stressgen Biotechnologies) or β-actin (Sigma, USA) at
4 °C overnight. After three washes with TBST, mem-
branes were incubated with horseradish peroxidase-
conjugated goat anti-rabbit IgG antibody for 2 h at
room temperature. Reactive protein was detected using
the ECL chemiluminescence system.
Detection of intestinal HO-1 mRNA by real-time PCR
To assess the expression of HO-1 by real-time PCR, total
RNA was extracted from intestine graft with TRIzol
(TakaRa, Japan). RNA (1 mg) was taken for reverse tran-
scription with a reaction volume of 30 ml. PCR was used
for HO-1 amplification and β-actin was used as an in-
ternal reference. Initial starting concentrations of cDNA
were determined by arbitrary units, and the ratio of HO-
1/β-actin was used to normalize the different samples.
Oligonucleotide primers (Yingjun Biosciences, Shanghai,
China) for HO-1 (forward, 5′-TCC CAG ACA CCG CTC
CTG CGA-3′; reverse, 5′-GGA TTT GGG GCT GCT
GGT TTC-3′) and β-actin (forward, 5′-ATT GCT GAC
AGG ATG CAG AAG-3′; reverse, 5′-AGA GCC ACC
AAT CCA CAC AGA-3′) were used. PCR conditions in-
cluded a primary denaturation time of 5 min at 94 °C,
followed by 33 cycles of 30 s at 94 °C, 30 s at 55 °C, and
45 s at 72 °C, and a final extension time of 5 min at 72 °C.
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Immunohistochemical detection of intestinal HO-1
The paraffin-embedded intestine tissue was sliced into
5-μm sections and deparaffinized, followed by 30-min
antigen retrieval using microwave treatment in 0.01 M
citrate buffer (pH 6.0). Tissue sections were then incu-
bated with 3% H2O2 for 20 min at room temperature
and blocked in goat serum for 30 min at 37 °C. After-
wards, the sections were incubated with the primary
antibody against HO-1 (Abcam, UK) at 4 °C overnight.
The following day, tissue sections were incubated with
the secondary antibody at room temperature for 1 h,
using goat anti-rabbit IgG (Dako, Japan) according to
the manufacturer’s instruction. Tissue sections were
then stained with 3,3′-diaminobenzidine and counter-
stained with hematoxylin.
Histological analysis
Intestinal tissues were processed by fixation in 10%
formalin, paraffin embedded, and then sliced into 5-μm
sections which were then stained with hematoxylin and
eosin (H&E). Slides were blindly examined by light
microscopy. Acute rejection was graded as described
previously [35].
Apoptosis assay
TdT-mediated dUTP-X nick end-labeling (TUNEL)
staining was performed and apoptosis-positive cells were
enumerated as described previously [34].
Natural killer cell activity
Host natural killer (NK) cell function was evaluated by
measuring lactate dehydrogenase (LDH) release following
coculture with the target YAC-1 cells as described in our
previous study [34]. Briefly, splenocytes and YAC-1 cells
were cocultured, and the optical density at 570 nm was
determined using an enzyme-linked immunosorbent assay
(ELISA) microplate reader (BioTek Winooski VT 05404,
USA) to calculate the level of NK cell activity.
Measurement cytokines concentrations by ELISA
Recipient serum samples were collected from periph-
eral blood at each time point and stored at –80 °C for
measurement. Interleukin (IL)-10, TGF-β, IL-2, IL-6,
IL-17, IL-23, tumor necrosis factor (TNF)-α, and inter-
feron (IFN)-γ concentrations were measured by ELISA
kits as described by the manufacturer (BioSource, USA)
and compared with standard curves.
Detection of regulatory T cells by flow cytometry
Regulatory T (Treg) cells were stained and analyzed by
flow cytometry as described previously [34]. Briefly, lym-
phocytes were isolated from the recipient spleens and
incubated with antibodies against CD4-FITC, CD25-PE,
and Foxp3-PerCP-Cyanine5.5 (eBioscience, San Diego,
CA, USA). The CD4+CD25+FoxP3+ cells were analyzed
by flow cytometry (FACSCalibur; BD).
Statistical analysis
Results are expressed as mean ± SD and were compared
by one-way analysis of variance. All statistical analyses
were performed using SPSS statistical software, v. 17.0
(SPSS GmbH, Munich, Germany), and P ≤ 0.05 was used
as a threshold to detect statistically significant differences.
Results
Characterization of Ad/HO-1/BMMSCs
In accordance with our previous study [33, 34], BMMSCs
isolated from rat bone marrow were spindle-shaped in
morphology and had abilities of adherence to plastic,
expressing specific surface molecules and multipotential
differentiation in vitro (data not shown). BMMSCs trans-
duced with recombinant adenovirus did not change in
terms of cellular morphology (Fig. 1a) and were confirmed
as BMMSCs based on their abilities for osteogenic dif-
ferentiation and adipogenic differentiation in vitro
(Fig. 1b, c). Ad/HO-1/BMMSCs were also identified
through detection of cell surface molecules. Flow cytome-
try showed that over 95% of these cells were positive for
CD29, CD90, and RT1A and were negative for CD34,
CD45, and RT1B (Fig. 1d–f ). The results demonstrated
that transduction with recombinant adenovirus did not
affect the molecular biological characteristics of BMMSCs.
HO-1 transduction improved HO-1 expression in BMMSCs
The immunohistochemical staining results revealed that
red fluorescence was visible with Ad/BMMSCs (Fig. 1g)
and Ad/HO-1/BMMSCs (Fig. 1h). Specifically, the fluores-
cence intensity was higher in Ad/HO-1/BMMSCs than that
in Ad/BMMSCs, especially 48 h after transduction. West-
ern blot analysis results showed significantly higher HO-1
expression in Ad/HO-1/BMMSCs than in BMMSCs (Fig.
1i). The results indicated that the HO-1 gene was success-
fully overexpressed when transduced into BMMSCs.
Improvement of recipient survival rates
The median recipient survival times were 10, 15, 14,
and 24 days in the allogeneic control group, BMMSC-
treated group, Ad/BMMSC-treated group, and Ad/HO-1/
BMMSC-treated group, respectively (Fig. 2). These results
clearly demonstrate a significant improvement in survival
rates in the Ad/HO-1/BMMSC group compared with the
other control groups.
Improvement of clinical manifestation and weight loss
Quality of life became worse with time in the allogeneic
control group. Clinical manifestations included asitia,
weight loss, less activity, nonresponsiveness to stimula-
tion, somnolence, and rat fur appearing scruffy and dull.
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These symptoms improved and the recipients were more
active and dynamic in the treatment groups, especially
in the Ad/HO-1/BMMSC group. Clinical manifestation
grading results showed markedly reduced scores in the
Ad/HO-1/BMMSC group compared with the controls
(Fig. 3a). Weight loss became more apparent over time
in each group as the dying animals were thin and bony
by gross observation (Fig. 3b). However, the weight loss
significantly improved with BMMSC treatment, espe-
cially when transduced with Ad/HO-1, as a comparison
with the allogeneic control group. We found the lowest
amount of weight loss in the Ad/HO-1/BMMSC group,
especially on days 7 and 10. The results indicated that
the general condition was better following Ad/HO-1/
BMMSC treatment than in controls.
Improvement of HO-1 protein and mRNA expression in
small bowel graft by Ad/HO-1/BMMSC infusion
Western blot analysis results showed minute levels of
HO-1 protein expression in the allogeneic control group.
Both the BMMSC-treated and the Ad/BMMSC-treated
Fig. 1 Characterization of Ad/HO-1/BMMSCs in vitro and detection of their HO-1 expression. (a) Morphology of Ad/HO-1/BMMSCs with a bright
field. BMMSCs exhibit spindle-shaped morphology and are arranged in whorls when transduced with Ad/HO-1. (b) Osteogenic differentiation of Ad/HO-1/
BMMSCs in vitro by Von Kossa staining. Black deposition of calcium salt can be seen in positive cells. (c) Adipogenic differentiation of Ad/HO-1/BMMSCs in
vitro by Oil Red O staining. Red lipid droplet formation can be seen in positive cells. Surface markers detection of Ad/HO-1/BMMSCs demonstrated that
the proportion of CD29-positive and CD34-negative cells was >97% (d), the proportion of CD90-positive and CD45-negative cells was >95%
(e), and the proportion of RT1A-positive and RT1B-negative cells was >96% (f). Immunocytochemical staining revealed that the red fluorescence intensity
(HO-1 expression level) in the cytoplasm was higher in the Ad/HO-1/BMMSC-treated group (h) than in the BMMSC-treated group (g). (i)
Western blot analysis results showed significantly higher HO-1 expression in Ad/HO-1/BMMSCs than in BMMSCs (*p < 0.05). Ad/HO-1 adenoviral vector
carrying the heme oxygenase gene, BMMSC bone marrow mesenchymal stem cell, HO-1 heme oxygenase-1
Fig. 2 Kaplan–Meier survival curves of SBTx recipients. Median
recipient survival times were 10, 15, 14, and 24 days, in the allogeneic
control (Allo) , BMMSC-treated, Ad/BMMSC-treated, and Ad/HO-1/
BMMSC-treated groups, respectively (n = 5 in each group). Survival
rates were significantly improved in the Ad/HO-1/BMMSC treatment
group compared with the control groups (P = 0.0018 vs allogeneic
control group; P = 0.0088 vs BMMSC-treated group; P = 0.0333 vs Ad/
BMMSC-treated group). Ad adenoviral vector, BMMSC bone marrow
mesenchymal stem cell, HO-1 heme oxygenase-1, SBTx small
bowel transplantation
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groups exhibited low-level and downward expression of
HO-1 protein. However, the Ad/HO-1/BMMSC treat-
ment group demonstrated high-level and steady expres-
sion of HO-1 protein. PCR results showed that HO-1
mRNA expression increased less than 2-fold in the
BMMSC-treated and the Ad/BMMSC-treated groups,
and increased between 2.5-fold and 4-fold in the Ad/
HO-1/BMMSC treatment group. Importantly, trans-
duction with Ad/HO-1 resulted in a significant and
steady increase in HO-1 gene expression compared
with the control groups (Fig. 4). Immunohistochemical
staining showed that HO-1 (stained brown) was
expressed mainly by infused cells that localized in the
lamina propria of the small intestine villi. Similar to the
results of the western blot analysis, HO-1 was weakly
detected in the allogeneic control group. Both the
BMMSC-treated and the Ad/BMMSC-treated groups ex-
hibited limited brown staining, while a greater amount of
brown staining was detected in the Ad/HO-1/BMMSC
treatment group (Fig. 5). These results suggest that
BMMSCs may localize in the small intestine graft and
function through HO-1 upregulation. HO-1 transduction
could improve BMMSC survival and expression of HO-1
in small intestine graft.
Improvement of small bowel graft histopathology and
grading of acute rejection by Ad/HO-1/BMMSC infusion
Acute cellular rejection (ACR) was graded as indetermin-
ate, mild, moderate, or severe, depending on findings in
the mucosa and submucosa, including cell infiltration,
crypt epithelial injury, apoptotic bodies in crypts, architec-
tural distortion, and mucosal ulceration as described pre-
viously [35]. Allogeneically transplanted animals treated
with normal saline showed a gradual increase in acute re-
jection, with moderate or severe acute rejection observed
on day 7. Animals in both the BMMSC treatment group
and the Ad/BMMSC treatment group showed reduced
ACR to different degrees. However, the protective effect
receded markedly after day 7, especially on day 10. ACR
was maximally suppressed in the Ad/HO-1/BMMSC-
treated group and the effect remained powerful 7 days
post SBTx, with minimal cellular infiltration into the
muscle layer and mucosa, fewest apoptotic cells, and mild-
est crypt destruction, compared with single BMMSC treat-
ment or Ad/BMMSC treatment (Fig. 6).
Reduction of apoptosis in small intestine mucosa by
Ad/HO-1/BMMSC infusion
Using TUNEL staining, we evaluated apoptotic cells in
graft mucosa after SBTx (Fig. 7a). The numbers of
apoptotic cells in the intestinal mucosa increased pro-
gressively in the normal saline allogeneic control group,
and reduced to different degrees in both the BMMSC
treatment group and the Ad/BMMSC treatment group.
Compared with the other three control groups, TUNEL-
positive apoptotic cells were least populated in the Ad/
HO-1/BMMSC group (Fig. 7b); in particular, Ad/HO-1/
BMMSC treatment significantly decreased cell apoptosis
in the graft mucosa. Acute rejection is associated with
increased apoptosis in the graft [36, 37]. The amount of
apoptotic body in crypts was one of the criteria for diag-
nosing the grade of acute rejection in SBTx [35]. Our
results indicated reduced acute rejection in all cell treat-
ment groups, especially in the Ad/BMMSC treatment
group.
Reduction of recipient NK cell activity by Ad/HO-1/BMMSC
infusion
NK cell activity increased rapidly in the allogeneic
control group, exceeding the normal range at all time
Fig. 3 Clinical manifestation grading and weight loss of the recipients
following SBTx. a Clinical manifestation scores were much higher in the
allogeneic control (Allo) group compared with the BMMSC treatment
group. HO-1 transduction markedly reduced the score, especially on days
7 and 10. b The majority of the animals suffered weight loss following
SBTx. BMMSC treatment, especially when transduced with Ad/HO-1,
significantly improved or even reversed this effect compared with the
allogeneic control group. The least amount of weight loss occurred in
the Ad/HO-1/BMMSC group, especially on days 7 and 10. Data expressed
as mean ± SD (*P< 0.05 compared with allogeneic controls; #P< 0.05
compared with BMMSC controls; $P< 0.05 compared with Ad/BMMSC
controls). Ad adenoviral vector, BMMSC bone marrow mesenchymal stem
cell, HO-1 heme oxygenase-1, SBTx small bowel transplantation
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points. While uptrend of NK cell activity was also
presented in both the BMMSC treatment group and the
Ad/BMMSC treatment group, the activity was signifi-
cantly reduced compared with the allogeneic control
group. Different to all three of these control groups, NK
cell activity in the Ad/HO-1/BMMSC treatment group
fluctuated within a small range and remained within the
normal range at almost all time points. The results indi-
cate that transduction with Ad/HO-1 successfully caused
BMMSCs to be more capable of reducing NK cell activity
after SBTx (Fig. 8). NK cell-mediated rejection in SBTx
was thus most reduced in the Ad/HO-1/BMMSC treat-
ment group, relative to the control groups.
Recipient serum cytokine concentrations
ELISA was performed to assay the serum concentrations
of inflammatory response-related cytokines and T-cell
differentiation-related cytokines such as Th1/Th2 and
Th17/Treg (Fig. 9). In the allogeneic control group, the
cytokine levels increased steadily after SBTx. Increases
in IL-2, TNF-α, and IFN-γ levels were much lower in
the BMMSC treatment group compared with the allo-
geneic control group. However, there was a sharp
increase in their concentrations on day 10 compared
with any other time points. Similarly, the Ad/BMMSC
group demonstrated rising trends of IL-2, TNF-α, and
IFN-γ levels between days 1, 5, 7, and 10, although these
levels were significantly reduced compared with the allo-
geneic control group. Serum IL-10 and TGF-β concen-
trations in both the BMMSC treatment group and the
Ad/BMMSC treatment group also increased rapidly
between days 1, 5, and 7, and peaked on day 10. The IL-
10 and TGF-β levels were significantly higher at each
time point in these groups compared with the allogeneic
control group. Moreover, IL-6, IL-17, and IL-23 concen-
trations in both the BMMSC group and the Ad/BMMSC
group demonstrated a downward trend within 7 days,
and an uptrend on day 10. These cytokine concentra-
tions were significantly decreased compared with the
allogeneic control group. As with the Ad/HO-1/BMMSC
Fig. 4 Expression of HO-1 protein and mRNA in the graft after SBTx. Expression of HO-1 in protein (a) and mRNA (b) was confirmed by western
blot assay and real-time PCR, respectively (n = 5 in each group). Relative content was determined by HO-1/β-actin ratio. High-level and steady
expression of HO-1 protein and mRNA were observed in the Ad/HO-1/BMMSC group (*P < 0.05 compared with allogeneic controls; #P < 0.05
compared with BMMSC controls; $P < 0.05 compared with Ad/BMMSC controls). Ad adenoviral vector, Allo allogeneic control, BMMSC bone mar-
row mesenchymal stem cell, HO-1 heme oxygenase-1, SBTx small bowel transplantation
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treatment group, concentrations of IL-2, TNF-α, and IFN-γ
exhibited a relative small increase; levels of IL-6, IL-17, and
IL-23 decreased further, while IL-10 and TGF-β concentra-
tions increased continuously with respect to both the
BMMSC and the Ad/BMMSC treatment groups. These
results indicated that HO-1-transduced BMMSCs could
maximally inhibit the inflammatory response, shift the
Th1/Th2 balance to Th2, and differentiate into more
Treg cells but fewer Th17 cells by maximally downreg-
ulating cytokines IL-2, IL-6, IL-17, IL-23, TNF-α, and
IFN-γ, while upregulating cytokines IL-10 and TGF-β.
Improvement of recipient spleen Treg cell levels by
Ad/HO-1/BMMSC infusion
The numbers of CD4+CD25+Foxp3+ Treg cells in the
spleens showed almost no change with time in the allo-
geneic control. In contrast, levels of Treg cells significantly
increased in both the BMMSC treatment group and the
Ad/BMMSC and Ad/HO-1/BMMSC treatment groups. In
particular, a downward trend of Treg cells presented on
day 10 in both the BMMSC and the Ad/BMMSC treat-
ment groups, while a continuous increase was observed in
the Ad/HO-1/BMMSC treatment group. In general, Treg
cell levels were significantly increased in the Ad/HO-1/
BMMSC treatment group (Fig. 10).
Discussion
Although outcomes in SBTx have improved greatly in
recent years, controlling graft rejection remains a big
concern. Morbidity associated with acute and chronic
rejection after SBTx has been reported as 90% and
30–50%, respectively [38]. Cell therapy, particularly in
the form of MSCs, has emerged as a novel technique
in suppressing the immune response after transplant-
ation, owing to MSCs causing fewer side effects com-
pared with immunosuppressants. While MSCs have
been used in multifarious organ transplants [39–41]
including SBTx [24, 42], there has been an increased
focus on overcoming transplantation limitations and
enhancing MSC function [43–47]. This study was de-
signed to investigate whether the cytoprotective and
immunosuppressive protein, HO-1, could improve the
survival rate of BMMSCs in vivo and reinforce SBTx
protection.
In this study, we first verified BMMSC transduction
with Ad/HO-1 to make sure recombinant adenovirus
transduction would not affect the BMMSCs, but medi-
ated expression of the target gene. Cellular morphology
and proliferation, in-vitro differentiation, and surface
molecule characterization of our results all demon-
strated that Ad/HO-1 did not alter the biological
Fig. 5 Immunohistochemical staining exhibiting HO-1 expression. HO-1 was detected primarily in the lamina propria of the small intestine villi
and stained brown. In the allogeneic control (Allo) group, HO-1 was weakly expressed and difficult to detect. Both the BMMSC and the Ad/BMMSC
treatment groups exhibited limited brown staining, while a greater amount of brown staining was detected in the Ad/HO-1/BMMSC treatment group.
Ad adenoviral vector, BMMSC bone marrow mesenchymal stem cell, HO-1 heme oxygenase-1
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properties of BMMSCs, which was in agreement with
previous studies [9, 43, 45]. Immunocytochemical stain-
ing revealed that the red fluorescence intensity in the
cytoplasm was higher, while western blot analysis
showed more HO-1 expression in Ad/HO-1/BMMSCs
than in BMMSCs and in Ad/BMMSCs, indicating that
the HO-1 gene was successfully overexpressed in the
cytoplasm of Ad/HO-1/BMMSCs.
HO-1 is well known for its anti-inflammatory, anti-
apoptosis, and cytoprotection properties. Recent stud-
ies have revealed its immunoregulatory role in MSCs,
and particularly its immunosuppressive effect [31, 48].
Because we have demonstrated that HO-1 can be overex-
pressed when transduced into BMMSCs, we wondered
whether overexpressed HO-1 in Ad/HO-1/BMMSCs could
enhance their survival in a small bowel graft, and whether
surviving cells expressed more HO-1. We therefore per-
formed immunohistochemistry, western blot analysis, and
PCR experiments to detect HO-1 expression in small
bowel grafts. The results reveal a significant increase in
expression of HO-1 protein and mRNA in the trans-
planted intestine in the Ad/HO-1/BMMSC treatment
group. Importantly, HO-1 was mainly expressed by
infused cells that localized in the lamina propria of the
small intestine villi. In keeping with our conjecture,
more BMMSCs survived in small bowel graft when
transduced with Ad/HO-1.
To make clear whether improved survival of BMMSCs
and the following HO-1 overexpression could be helpful
to further reduce acute rejection, SBTx rejection was
assessed histologically in a major histocompatibility
complex (MHC)-disparate rat strain combination
Fig. 6 Histological sections of the rat small bowel and grading of ACR after SBTx. a Histological sections showing the pathologic changes in the
small bowel in each group (H&E staining; magnification × 100). b Histogram of acute rejection grading (n= 5 in each group; *P< 0.05 compared with
allogeneic controls; #P< 0.05 compared with BMMSC controls; $P< 0.05 compared with Ad/BMMSC controls). Ad adenoviral vector, Allo allogeneic control,
BMMSC bone marrow mesenchymal stem cell, HO-1 heme oxygenase-1, SBTx small bowel transplantation
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(BN to Lewis). Histological analysis showed that acute
rejection gradually increased and reached moderate or se-
vere levels on day 7 in the allogeneic control group, with
massive destruction of crypt architecture, apoptosis, and
heavy infiltration with neutrophils and lymphocytes. Both
the BMMSC treatment group and the Ad/BMMSC treat-
ment group presented alleviative acute rejection, with
mild crypt distortion, apoptosis, and infiltration. In the
Ad/HO-1/BMMSC treatment group, crypt distortion,
apoptosis, and inflammatory cell infiltration were
observed more rarely and the architectures were more in-
tegrated, indicating further attenuation of acute rejection.
Grading of acute rejection significantly decreased in the
Ad/HO-1/BMMSC treatment group, especially in the later
stages, compared with the reduction in the BMMSC treat-
ment group and the Ad/BMMSC treatment group. In
addition, the recipient survival rate and quality of life
factors such as weight loss significantly improved with al-
leviation of acute rejection.
The broad mechanisms of acute rejection in SBTx
involve T-cell-mediated and antibody-based forms,
which are similar to those in other organ systems.
Fundamentally, the adaptive immune response, princi-
pally comprised of recipient-derived T-cell and B-cell
subpopulations, has a complex interplay with innate
Fig. 7 Apoptotic cells in graft mucosae. a Histological sections from each rat group at each time point were subjected to TUNEL staining
(magnification × 200). b Histogram showing the percentage of positive apoptotic signals in each group on days 1, 5, 7, and 10 (n = 5 in each
group). Apoptotic cells in graft mucosae increased rapidly in the allogeneic control (Allo) group; the increase was significantly inhibited by both
BMMSC and Ad/BMMSC treatment. TUNEL-positive apoptotic cells further decreased in the Ad/HO-1/BMMSC treatment group compared with the
treatment control groups. Data expressed as mean ± SD (P < 0.05 compared with the allogeneic controls; #P < 0.05 compared with the BMMSC
controls; $P < 0.05 compared with the Ad/BMMSC controls). Ad adenoviral vector, BMMSC bone marrow mesenchymal stem cell, HO-1 heme
oxygenase-1, TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling
Fig. 8 NK cell activity evaluated by measuring LDH release in mixed
culture with YAC-1 cells. NK cell activity was significantly inhibited by
BMMSC treatment or even dropped to the normal range when
treated with Ad/HO-1/BMMSCs. Data expressed as mean ± SD (n = 5
in each group; *P < 0.05 compared with allogeneic controls; #P < 0.05
compared with BMMSC controls; $P < 0.05 compared with Ad/BMMSC
controls). Ad adenoviral vector, Allo allogeneic control, BMMSC bone
marrow mesenchymal stem cell, HO-1 heme oxygenase-1, NK natural
killer, SBTx small bowel transplantation
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immune populations including NK cells, dendritic cells,
innate lymphoid cells, and macrophages [49]. Our study
assessed several crucial aspects involving NK cell activity,
T-cell subpopulations, and related cytokines to determine
the effect of Ad/HO-1/BMMSCs on acute rejection.
NK cells mediate the non-MHC-restricted killing of
virally infected and neoplastic cells and are involved in
regulating the immune responses. Human NK cells me-
diate the rejection of both allogeneic bone marrow and
xenogeneic solid organ grafts [50, 51]. We observed a
Fig. 9 IL-10, TGF-β, IL-2, IL-6, IL-17, IL-23, TNF-α, and IFN-γ concentrations in recipient serum. ELISA revealed cytokine concentrations in the recipient
serum on days 1, 5, 7, and 10 after transplantation (n = 5 in each group). Data expressed as mean ± SD (*P < 0.05 compared with allogeneic controls;
#P < 0.05 compared with BMMSC controls; $P < 0.05 compared with Ad/BMMSC controls). Ad adenoviral vector, Allo allogeneic control, BMMSC bone
marrow mesenchymal stem cell, HO-1 heme oxygenase-1, SBTx small bowel transplantation
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significant increase in NK cell activity in the allogeneic
control group. NK cell activity was reduced but still
higher than normal in both the BMMSC treatment
group and the Ad/BMMSC treatment group. Moreover,
NK cell activity decreased to normal when treated with
Ad/HO-1/BMMSCs.
Inflammation-related cytokines and T-cell differentiation-
related cytokines play an important role in transplantation
immunology. The Th1 cell subset mainly secretes IL-2,
IFN-γ, and TNF-α, whereas Th2 cells mainly produce
IL-4, IL-10, and IL-13. The Th1/Th2 paradigm and the
cytokines related to these cells have been used to
explain transplantation-related phenomena in immun-
ity [52–54]. A previous study demonstrated that IL-2
was significantly elevated in acute rejection and corre-
lated highly with the severity of rejection [55]. In
contrast, high levels of IL-10 have been associated with
the acceptance of solid allografts and even the induc-
tion of transplantation tolerance [56]. Furthermore, the
IL-2/IL-10 ratio has been reported to be useful for the
diagnosis of rejection in SBTx [57]. Also, TNF-α
concentrations reportedly participate in acute rejection
in organ transplantation [58–60]. The Th17/Treg axis
switch serves a key function in regulating the immune
responses in both organ transplantation and autoimmune
disease [61, 62]. Therefore, we next assessed the regula-
tion of Treg/Th17 according to their related cytokine se-
cretion. Th17 cells are characterized by the production of
IL-17, IL-21, and IL-22 [63, 64], and their differentiation
requires TGF-β and IL-6 [65]. Stabilization of the Th17
cell phenotype is driven by IL-23, along with TNF-α and
IL-1β [66]. Thus, we think measurement of these cytokine
changes indirectly informs on T-cell polarization. We
found that IL-10 and TGF-β were associated with Treg
cells, while IL-6, IL-17, IL-23, TNF-α, and IFN-γ were as-
sociated with Th17. Our ELISA results revealed that the
anti-inflammatory and Treg-associated cytokines, IL-10
and TGF-β, were significantly higher in the Ad/HO-1/
BMMSC-treated group compared with the control groups.
In contrast, the proinflammatory and Th17-associated
cytokines IL-2, IL-6, IL-17, IL-23, TNF-α, and IFN-γ,
reduced to different degrees in the treatment groups. It
is worth noting that the effect was more powerful in
the Ad/HO-1/BMMSC treatment group.
Treg cells are a subset of T cells that express Foxp3.
Treg cells have anti-inflammatory functions and can
promote tolerance to “self” by contact-mediated sup-
pression or secretion of the anti-inflammatory cytokines
Fig. 10 Expression of Treg cells in recipient spleen. a Scatter plot of Treg cells by flow cytometry. b Histogram showing the percentages of Treg
cells on days 1, 5, 7, and 10 (n = 5 in each group). Levels of Treg cells increased steadily in the Ad/HO-1/BMMSC treatment group compared with
the three control groups. Data expressed as mean ± SD (*P < 0.05 compared with allogeneic controls; #P < 0.05 compared with BMMSC controls;
$P < 0.05 compared with Ad/BMMSC controls). Ad adenoviral vector, Allo allogeneic control, BMMSC bone marrow mesenchymal stem cell, HO-1
heme oxygenase-1, SBTx small bowel transplantation
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IL-10 and TGF-β [67–71]. We demonstrated previously
that expression of Treg cells is one of the mechanism by
which BMMSCs display their immunosuppressive effect
after SBTx [34]. Now, we reveal a further improvement
in the levels of Treg cells in the Ad/HO-1/BMMSC
treatment group compared with both the BMMSC and
the Ad/BMMSC treatment groups.
Conclusions
In summary, this study demonstrates that transduction
with Ad/HO-1 significantly suppresses acute rejection
after SBTx, improving both the survival rate of the SBTx
recipient and the clinical outcomes of the procedure. We
attribute this to the overexpression of HO-1, which
enhances the immunosuppressive effect of BMMSCs
through reduction of ACR, apoptosis, NK cell activity, and
regulation of related cytokines and Treg cell expansion.
Therefore, we conclude that HO-1 gene-modified
BMMSCs play a reinforced effect in protecting the out-
come of SBTx in rats.
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